Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Carol Aghajanian et al.|Gynecologic Oncology|2015Cited by 300
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersElizabeth Page, Manuel R. Teixeira, Jennifer Pope et al.|European Urology|2019Cited by 239
Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)Helen Hanson, Douglas R. Stewart, Esteban Astiazarán-Symonds et al.|Genetics in Medicine|2023Cited by 79